Nebivolol in current practice from specialist perspective Discussion
Article Sidebar
Published:
Sep 30, 2017
Keywords:
nebivolol, clinical practice, scientific data
Main Article Content
Abstract
When choosing a therapy in practice, we are guided by the criteria used in clinical situations, which have been verified in the studies, registered indications and specific characteristics of selected drugs. The paper presents a discussion on the choice of specific β-blockers with many different pharmacological features, additional properties or registered indications.
Article Details
How to Cite
Grabowski , M., & Prejbisz , A. (2017). Nebivolol in current practice from specialist perspective. Medycyna Faktow (J EBM), 10(3(36), 210-212. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2125
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.
2. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013; 31: 1281-1357.
3. Czuriga I., Riecansky I., Bodnar J. et al.: Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc. Drugs Ther. 2003; 17: 257-263.
4. Bangalore S., Sawhney S., Messerli F.H.: Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J. Am. Coll. Cardiol. 2008; 52: 1482-1489.
5. Kampus P., Serg M., Kals J. et al.: Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness.Hypertension 2011; 57: 1122-1128.
6. Centralne ciśnienie tętnicze. Biblioteka Czasopisma Nadciśnienie Tętnicze 2010. Wydawnictwo Medyczne Via Medica, 2010.
7. Jankowski P., Kawecka-Jaszcz K.: Centralne ciśnienie tętnicze. Biblioteka Czasopisma Nadciśnienie Tętnicze 2010. Wydawnictwo Medyczne Via Medica, 2010.
8. Münzel T., Gori T.: Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J. Am. Coll. Cardiol. 2009; 54(16): 1491-1499.
2. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013; 31: 1281-1357.
3. Czuriga I., Riecansky I., Bodnar J. et al.: Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc. Drugs Ther. 2003; 17: 257-263.
4. Bangalore S., Sawhney S., Messerli F.H.: Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J. Am. Coll. Cardiol. 2008; 52: 1482-1489.
5. Kampus P., Serg M., Kals J. et al.: Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness.Hypertension 2011; 57: 1122-1128.
6. Centralne ciśnienie tętnicze. Biblioteka Czasopisma Nadciśnienie Tętnicze 2010. Wydawnictwo Medyczne Via Medica, 2010.
7. Jankowski P., Kawecka-Jaszcz K.: Centralne ciśnienie tętnicze. Biblioteka Czasopisma Nadciśnienie Tętnicze 2010. Wydawnictwo Medyczne Via Medica, 2010.
8. Münzel T., Gori T.: Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J. Am. Coll. Cardiol. 2009; 54(16): 1491-1499.